News

The Manila Times47m
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA ...
Hosted on MSN58m
Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML
On June 24, Syndax announced that the US FDA granted Priority Review for its supplemental New Drug Application (sNDA) for ...